Does stopping Ozempic or Wegovy cause weight regain?

The short answer

Most people who stop semaglutide or tirzepatide regain a substantial share of the weight they lost, and it happens fast. Randomized trials agree on this. But the largest real-world study to date, a 2026 Cleveland Clinic analysis of nearly 8,000 patients, found regain that was smaller and less universal than the trial data predict. The likely reason: many real-world patients restart treatment or switch to a different drug before regain gets far. Both are real. The gap between them is one of the more important open questions in GLP-1 medicine right now.

What the randomized trials show

The clearest data come from the STEP 1 trial extension. Participants took semaglutide 2.4 mg (the Wegovy dose) for 68 weeks and lost a mean 17.3% of body weight. Then 327 of them stopped the drug and were followed for another year. They regained 11.6 percentage points of that loss on average, leaving a net loss of just 5.6% from where they started. The comparison group, on placebo the whole time, regained only 1.9 points after their own lifestyle program ended, for a net loss of 0.1%. Essentially back to baseline.

That placebo arm matters. Some rebound is built into ending any structured weight intervention, drug or no drug. But the treated group’s regain ran about six times larger, which points to a pharmacologic effect on top of the general one.

SURMOUNT-4 shows the same pattern with tirzepatide (Zepbound/Mounjaro). After 36 weeks of treatment and a 20.9% mean weight loss, 670 participants were randomized to keep taking the drug or switch to placebo. Over the next 52 weeks, the switchers regained a mean 14 percentage points. Most regained 25% or more of what they’d lost within the year. The group that stayed on tirzepatide lost another 5.5%.

It’s not just the scale number

A post hoc analysis of SURMOUNT-4 published in JAMA Internal Medicine in 2026 looked past body weight to the metabolic gains after stopping tirzepatide. Waist circumference, non-HDL cholesterol, fasting insulin, blood pressure, and blood sugar markers all reversed in proportion to how much weight came back. But people who regained less than 25% of their lost weight showed no significant reversal in waist circumference, non-HDL cholesterol, or fasting insulin. Partial maintenance still protects some of the benefit. Full regain erases most of it.

How fast does it come back

Two 2026 meta-analyses tried to pin down the speed of regain across studies.

A nonlinear meta-regression in eClinicalMedicine pooled six randomized trials covering 3,236 participants and estimated that 60% of on-treatment weight loss was back one year after stopping a GLP-1 drug. Projected past the actual follow-up window, the same analysis modeled a plateau at 75.3% of the lost weight (95% CI 68.9-81.6%). A caveat on that plateau: the underlying trials followed patients for 52 weeks. The estimate is an extrapolation built with an exponential recovery function, not something anyone directly measured. Treat it as a modeled projection, not an observed outcome.

A separate Bayesian hierarchical meta-analysis, pooling 1,776 participants across 6 studies with follow-up ranging from 4 to 52 weeks, put the regain rate at 1.04 kg per month after a mean on-treatment loss of 15.35 kg. Extrapolated forward, that works out to 50% of lost weight back by 7.5 months and a full return to baseline by 15 months (95% credible interval 10.1-21.1 months). Same caveat here: the input data ran to 52 weeks. The 15-month full-return figure is a projection, and the wide credible interval reflects how much uncertainty that projection carries.

The broadest look comes from a January 2026 systematic review and meta-analysis covering 37 studies and 9,341 adults who stopped any weight-management medication, not just GLP-1 drugs, after a mean 39 weeks of treatment. Across all drugs, regain averaged 0.4 kg per month. For semaglutide and tirzepatide specifically, it ran 0.8 kg per month, roughly 0.3 kg per month faster than regain after stopping behavioral weight-management programs. Newer, more potent drugs appear to come with a steeper drop-off.

None of these studies isolate whether tapering the dose slowly, rather than stopping abruptly, changes the trajectory. That question is open.

Where real-world data complicates the picture

A March 2026 Cleveland Clinic retrospective cohort study looked at 7,938 adults in Ohio and Florida who discontinued injectable semaglutide or tirzepatide after 3 to 12 months of use. The results came in milder than the trial data. Among patients treated for obesity, 55% gained weight in the year after stopping, which means 45% maintained their loss or kept losing. Among patients treated for type 2 diabetes, only 44% gained weight at all.

Why the gap with trial data? The researchers offer a practical explanation: many patients in this cohort restarted their original drug or switched to a different obesity treatment during the follow-up year. Clinical trial placebo arms can’t do that by design. They stay off the drug no matter what happens to their weight. Real patients see the number on the scale moving and go back to their doctor.

Trial data describe what happens if you stop and stay stopped. Real-world data describe what happens when people can restart, and many take that option. The tension is genuine and unresolved, not a footnote.

What this means if you’re considering stopping

If you’re thinking about coming off semaglutide or tirzepatide, whether for cost, side effects, or a goal you’ve reached, the honest summary is this: expect meaningful regain within the first year, and expect it to arrive faster than the loss did. If the regain is substantial, expect at least some reversal of the blood pressure, cholesterol, and blood sugar improvements. Keeping regain under roughly a quarter of what you lost appears to preserve most of the metabolic benefit, based on the SURMOUNT-4 analysis.

None of the cited research supports the idea that a specific diet, supplement, or off-label regimen prevents this rebound. No study in this evidence base tested such an intervention in humans. If your provider recommends a maintenance strategy, have that conversation with them directly rather than self-managing from regain statistics.

Cost often drives the decision to stop in the first place. If that’s you, it’s worth comparing options before deciding: current Wegovy pricing, the monthly cost of semaglutide more broadly, and how compounded semaglutide pricing compares, especially given the semaglutide compounding rule changes taking effect in June 2026.

Frequently Asked Questions

Do you always regain all the weight after stopping Ozempic or Wegovy? No. The STEP 1 extension found participants who stopped semaglutide had regained about two-thirds of their lost weight within a year, not all of it. Meta-analyses project further regain toward baseline over 15 to 18 months, but that later stretch is modeled, not directly observed past 52 weeks. Real-world Cleveland Clinic data show smaller average regain than trials, likely because many patients resumed treatment before regain went further.

How fast does the weight come back? Pooled estimates put it around 0.8 to 1.04 kg per month for semaglutide and tirzepatide, based on the January 2026 systematic review and the Bayesian meta-analysis. These are averages across pooled data with wide individual variation, and most of the underlying follow-up ran 52 weeks or less.

Does stopping reverse the health benefits, not just the weight? Yes, and the degree tracks with how much weight comes back. The SURMOUNT-4 post hoc analysis found that people who regained less than 25% of their lost weight kept most of their cardiometabolic improvements, including waist circumference and cholesterol. Partial weight maintenance still has real value.

Is real-world regain the same as what’s seen in clinical trials? No, and the gap is real, not something to smooth over. The Cleveland Clinic cohort found milder, less universal regain than randomized trials show. Trial placebo groups are barred from restarting treatment; real-world patients frequently do, or they switch drugs, once they notice weight coming back.

Does regain differ between semaglutide and tirzepatide? The evidence is inconclusive. The Bayesian meta-analysis found numerically faster unadjusted regain on tirzepatide, but no clear independent difference between the drugs once other factors were accounted for. There isn’t a solid basis yet to say one drug is worse than the other for rebound weight.

This article is for informational purposes only and is not medical advice. Talk to your healthcare provider before starting, stopping, or changing any medication.